MedTrace Logo

Buprenorphine Dose Alteration Study - 1

NCT00000219 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL

Last updated 2016-05-06

No results posted yet for this study

Summary

The purpose of this study is to examine the effects in buprenorphine dose alterations in opioid dependent individuals being maintained on buprenorphine.

Conditions

  • Opioid-Related Disorders

Interventions

DRUG

Buprenorphine

Sponsors & Collaborators

  • National Institute on Drug Abuse (NIDA)

    collaborator NIH

  • University of Vermont

    lead OTHER

Principal Investigators

  • Warren Bickel, Ph.D. · University of Vermont

Study Design

Purpose
TREATMENT
Masking
DOUBLE

Eligibility

Min Age
19 Years
Max Age
41 Years
Sex
MALE
Healthy Volunteers
No

Timeline & Regulatory

Start
1991-12-31
Completion
2001-07-31

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00000219 on ClinicalTrials.gov